QUDEXY XR Topiramate Extended Release Capsules: payments to doctors
Payments that named QUDEXY XR Topiramate Extended Release Capsules as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $234K
- Providers
- 3,063
- Transactions
- 7,723
- Average per transaction
- $30
The per-transaction average — $30 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,063 providers the average total is $77, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Upsher-smith Laboratories LLC | $234,466 | 100.0% |